Clinigen Group PLC (CLIN) Stock Rating Reaffirmed by Royal Bank Of Canada

Clinigen Group PLC (LON:CLIN)‘s stock had its “outperform” rating reiterated by research analysts at Royal Bank Of Canada in a note issued to investors on Tuesday. They currently have a GBX 1,360 ($17.89) price target on the stock. Royal Bank Of Canada’s target price points to a potential upside of 25.46% from the stock’s current price.

Other research analysts have also recently issued research reports about the stock. Numis Securities Ltd cut shares of Clinigen Group PLC to an “add” rating and set a GBX 1,100 ($14.47) price objective for the company. in a report on Tuesday, July 18th. Peel Hunt restated an “add” rating and issued a GBX 1,200 ($15.78) price objective on shares of Clinigen Group PLC in a report on Thursday, September 28th. Finally, Berenberg Bank initiated coverage on shares of Clinigen Group PLC in a report on Wednesday, November 1st. They issued a “hold” rating and a GBX 1,200 ($15.78) price objective for the company. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of GBX 1,145.83 ($15.07).

Clinigen Group PLC (LON CLIN) opened at GBX 1,084 ($14.26) on Tuesday. Clinigen Group PLC has a twelve month low of GBX 695 ($9.14) and a twelve month high of GBX 1,187 ($15.61).

Clinigen Group PLC (LON:CLIN) last announced its quarterly earnings data on Thursday, September 28th. The company reported GBX 41.80 ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of GBX 41.20 ($0.54) by GBX 0.60 ($0.01). The firm had revenue of £302.30 million during the quarter. Clinigen Group PLC had a net margin of 0.70% and a return on equity of 0.98%.

ILLEGAL ACTIVITY WARNING: “Clinigen Group PLC (CLIN) Stock Rating Reaffirmed by Royal Bank Of Canada” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://ledgergazette.com/2017/11/09/clinigen-group-plc-clin-stock-rating-reaffirmed-by-royal-bank-of-canada.html.

In related news, insider John Bacon sold 250,000 shares of Clinigen Group PLC stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of GBX 1,093 ($14.38), for a total value of £2,732,500 ($3,593,976.06). Also, insider Shaun Edward Chilton sold 100,000 shares of Clinigen Group PLC stock in a transaction that occurred on Friday, October 13th. The stock was sold at an average price of GBX 1,150 ($15.13), for a total transaction of £1,150,000 ($1,512,560.83).

About Clinigen Group PLC

Analyst Recommendations for Clinigen Group PLC (LON:CLIN)

Receive News & Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply